The Evolution and Recent Advances in Diagnostic Criteria for Idiopathic Multicentric Castleman Disease
American Journal of Hematology · 2025-11 · 100 (11) · 2064-2073
DOI: 10.1002/ajh.70039 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Hematology, online erschienen am 21.08.2025. Verfasst von Fnu Alnoor und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA. Hauptthemen laut MEDLINE: Castleman Disease. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Recordati Rare Diseases, Department of Pathology at the University of Utah.
Abstract (Originalsprache)
Idiopathic multicentric Castleman disease (iMCD) is a rare cytokine‐driven disorder characterized by systemic inflammation, organ dysfunction, and altered lymph node microscopic architecture. Over the past decade, diagnostic criteria have evolved significantly, integrating clinical, histopathological, and molecular biomarker advancements. Key drivers of iMCD pathogenesis, such as interleukin‐6 dysregulation and other dysfunctional cytokine signaling, have been identified and led to the development of targeted therapies like siltuximab and tocilizumab. Histopathologic refinements have highlighted distinct subtypes, such as hypervascular, plasmacytic, and mixed histologic patterns, while molecular discoveries have unveiled potential paraneoplastic and clonal processes. Emerging technologies, including single‐cell sequencing, spatial transcriptomics, and digital pathology, offer promise in refining diagnostic precision and advancing personalized medicine. This review synthesizes historical frameworks, recent breakthroughs, and future directions in iMCD diagnostics, emphasizing the importance of multidisciplinary approaches for improved patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.
- ARUP Laboratories, Department of Pathology, University of Utah, Salt Lake City, Utah, USA.
- Division of Pathology, Department of Diagnostic Medicine, The University of Texas at Austin, Austin, Texas, USA.
- Department of Pathology, University of California, San Francisco, California, USA.
- Department of Pathology, Stanford University, Stanford, California, USA.
- Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
ORCID-Profile: Matt X Luo, Karen M Chisholm, David Ng, Peng Li, Robert S Ohgami
Förderung
- Recordati Rare Diseases
- Department of Pathology at the University of Utah
Zitieren
APA
Alnoor, F., Spies, N. C., Kumar, J., Samghabadi, P., Silva, O., Luo, M. X., Chisholm, K. M., Zhang, J., Rangel, A., Ng, D., Li, P., & Ohgami, R. S. (2025). The Evolution and Recent Advances in Diagnostic Criteria for Idiopathic Multicentric Castleman Disease. American Journal of Hematology, 100(11), 2064-2073. https://doi.org/10.1002/ajh.70039
Vancouver
Alnoor F, Spies NC, Kumar J, Samghabadi P, Silva O, Luo MX, et al. The Evolution and Recent Advances in Diagnostic Criteria for Idiopathic Multicentric Castleman Disease. American Journal of Hematology. 2025;100(11):2064-2073. doi:10.1002/ajh.70039
BibTeX
@article{Alnoor2025,
author = {Alnoor, Fnu and Spies, Nicholas C and Kumar, Jyoti and Samghabadi, Peyman and Silva, Oscar and Luo, Matt X and Chisholm, Karen M and Zhang, Jingjing and Rangel, Alexandra and Ng, David and Li, Peng and Ohgami, Robert S},
title = {The Evolution and Recent Advances in Diagnostic Criteria for Idiopathic Multicentric Castleman Disease},
journal = {American Journal of Hematology},
year = {2025},
volume = {100},
number = {11},
pages = {2064--2073},
doi = {10.1002/ajh.70039}
}
EUVIMED